Q2 Earnings Estimate for Envista Issued By Leerink Partnrs

Envista Holdings Corporation (NYSE:NVST) – Research analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for Envista in a report released on Monday, July 14th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.23 per share for the quarter, up from their prior forecast of $0.22. The consensus estimate for Envista’s current full-year earnings is $1.00 per share. Leerink Partnrs also issued estimates for Envista’s Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $1.00 EPS, FY2026 earnings at $1.13 EPS and FY2027 earnings at $1.33 EPS.

A number of other research firms have also recently commented on NVST. Morgan Stanley set a $16.00 target price on Envista in a research note on Tuesday, April 15th. Piper Sandler reduced their target price on Envista from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Baird R W raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th. Bank of America cut their price target on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, UBS Group reduced their price target on shares of Envista from $21.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.23.

Envista Trading Down 0.6%

NVST stock opened at $19.70 on Wednesday. Envista has a twelve month low of $14.22 and a twelve month high of $23.00. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -3.02, a price-to-earnings-growth ratio of 1.25 and a beta of 1.00. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $18.83 and its two-hundred day simple moving average is $18.53.

Envista (NYSE:NVST) last released its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.04. The firm had revenue of $616.90 million for the quarter, compared to the consensus estimate of $608.17 million. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its position in Envista by 1,985.1% during the first quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company’s stock valued at $78,547,000 after purchasing an additional 4,332,541 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares in the last quarter. Brickwood Asset Management LLP purchased a new position in shares of Envista in the 4th quarter worth approximately $40,037,000. Norges Bank purchased a new position in shares of Envista in the 4th quarter worth approximately $38,052,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Envista by 24.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company’s stock worth $144,760,000 after acquiring an additional 1,625,206 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.